Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sequencing Shows Promise for Diagnosing Prosthetic Joint Infections

By LabMedica International staff writers
Posted on 07 May 2019
A method is being developed for diagnosing infections associated with prosthetic joint implants that promises to provide results in a matter of hours as opposed to a week or more. More...
The current gold standard is bacterial culture from periprosthetic tissue samples collected during surgery, although another option is culturing from sonicated explanted prostheses in saline.

Of approximately 113,000 total knee replacement surgeries performed in the UK in 2017, 6,500, or about 6%, were revision surgeries, and nearly a quarter of those surgeries took place because of an infection or suspicion of infection. Elbow replacement surgeries showed similar rates of infection-related revision surgeries, while shoulder and hip replacements were around 17%and 16% respectively.

A team of scientists associated with the University of Oxford (Oxford, UK) devised a workflow involved removing a prosthetic device during surgery then placing it in saline and sonicating it to obtain approximately 40 mL of sonication fluid, which is essentially the largest volume they can easily handle in the laboratory, which is allowed them to maximize the number of cells they can extract DNA from. The sonication step potentially increases the number of bacterial cells available in the sample because it disrupts the bacterial biofilm. The DNA is extracted from the sonicated samples, cleaned, and prepared into libraries, which are then sequenced. The work leveraged Oxford Nanopore sequencing technologies.

Teresa Street, PhD, a postdoctoral research student at Nuffield Department of Clinical Medicine (Oxford, UK) and a co-author of the study said, discussed her group's attempts to validate the technology as part of a completely culture-free method for diagnosing prosthetic joint implant infections. She said “That the current gold standard is bacterial culture from periprosthetic tissue samples collected during surgery, although another option is culturing from sonicated explanted prostheses in saline. However, culture from tissue samples is relatively insensitive, with detection rates around 65% and is a very busy process with many steps.”

Their analyses using this improved protocol have a high degree of concordance with culture testing, and in fact they have been able to detect positives for certain species that were culture-negative. In addition, in a few Staphylococcus-positive cases so far they have been able to identify antimicrobial resistance genes. In one sample, they were able to detect two different Staphylococcus organisms, one of which they could identify (S. haemolyticus) and one of which they could not.

They later used MALDI-ToF mass spectrometry to identify this organism as S. caprae, and realized they couldn't initially detect it because it was not in their reference database, underscoring the fact that metagenomic sequencing is only as good as the reference database being used. The study was presented at the European Congress of Clinical Microbiology and Infectious Diseases held April 13-16, 2019, in Amsterdam, The Netherlands.

Related Links:
University of Oxford
Nuffield Department of Clinical Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Urinalysis Solution
UN-9000
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.